Search Results

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present data from a study investigating the mechanisms of BETR-001 (2-bromo-LSD) at the upcoming FENS conference on June 25-29 in Vienna, Austria.

Convergent Imaging Solutions, a leader in workflow optimized medical image fusion and nuclear medicine software, announced that it has won the public tender for nuclear medicine processing software at Hôpital Montfort, in Ottawa, Canada.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Pfizer is proud to announce that it is supporting a McMaster University-led study, through the Ontario Clinical Oncology Group, that aims to improve care for Canadians living with multiple myeloma.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

NORTH CHICAGO, ILLINOIS, May 15, 2024 — Rosalind Franklin University’s Helix 51 biomedical incubator, the only one of its kind in Lake County, Illinois, celebrated its fifth year of...

Intensity Therapeutics, Inc. along with The Ottawa Hospital and Ontario Institute of Cancer Research, will present updated data from the INVINCIBLE study, a randomized, phase 2 presurgical window of opportunity trial for Intensity’s intratumoral INT230-6 comprising SHAO, vinblastine and cisplatin, that is evaluating clinical and biological effects in patients with early-stage operable breast cancer.